Effects on mycophenolate mofetil vs cyclosporine administration on graft survival and function after islet allotransplantation in diabetic rats

World Journal of Gastroenterology

Volumn 11, Issue 18, 2005, Pages 2733-2738

  Fotiadis, Constantin ^a   Xekouki, Paraskevi ^a   Papalois, Apostolos E ^b   Antonakis, Pantelis T ^a   Sfiniadakis, Ioannis ^c   Flogeras, Dimitrios ^c   Karampela, Eleutheria ^b   Zografos, George ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Experimental Research Unit   (Greece)

^c ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Cyclosporine; Diabetes; Islet transplantation; Mycophenolate mofetil; Rats

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STREPTOZOCIN;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MALE; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PARENCHYMA; RAT; RAT STRAIN; SPLEEN; STATISTICAL SIGNIFICANCE;

EID: 18944406424     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i18.2733     Document Type: Article

References (49)

1. Robertson RP. Islet Transplantation as a Treatment for Diabetes-A Work in Progress. N Engl J Med 2004; 350: 694-705
2. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72: 175-186
3. Reckard CR, Ziegler MM, Barker CF. Physiological and immunological consequences of transplanting isolated pancreatic islets. Surgery 1973; 74: 91-99
4. Thomas DR, Fox M, Grieve AA. Isolation of islets of Langerhans for transplantation. Nature 1973; 242: 258-260
5. Alejandro R, Lehmann R, Riccordi C, Kenyon NS, Angelico MC, Burke G, Esquenazi V, Nery J, Betancourt AE, Kong SS, Miller J, Mintz DH. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997; 46: 1983-1989
6. Oberholzer J, Triponez F, Mage R, Andereggen E, Buhler L, Cretin N, Fournier B, Goumaz C, Lou J, Philippe J, Morel P. Human islet transplantation: Lessons from 13 autologous and 13 allogeneic transplantations. Transplantation 2000; 69: 1115-1123
7. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238
8. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton Protocol. Diabetes 2001; 50: 710-719
9. Hirshberg B, Rother KI, Digon BJ 3rd, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for Type 1 diabetes using steroid-sparing immunosuppression. Diabetes Care 2003; 26: 3288-3295
10. Titus TH, Badet L, Gray DWR. Islet cell transplantation for insulin-dependant diabetes mellitus: perspectives from the present and prospects for the future. Available from: http://www-ermm.cbcu.cam.ac.ac.uk//00001861h.htm
11. International islet transplant registry. Newsletter 9 2001; 8: 4-18
12. Braun F. Update of current immunosuppressive drugs in clinical organ transplantation. Transpl Int 1998; 11: 77-81
13. Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care 2001; 7: 242-250
14. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporine: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001; 61: 1957-2016
15. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, Ostenson CG, Gustafsson J, Efendic S, Okret S. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997; 100: 2094-2098
16. Yale JF, Roy RD, Grose M, Seemayer TA, Murphy GF, Marliss EB. Effects of Cyclosporine on Glucose Tolerance in the rat. Diabetes 1985; 34: 1309-1313
17. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou JC. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402
18. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993; 14: 353-380
19. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205-3210
20. Allison AC, Hovi T, Watts RWE, Webster ADB. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977; 48: 207-223
21. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118
22. Rosenberg AS, Singer A. Cellular basis of skin graft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992; 10: 333-358
23. Mathew TH. A blinded, long term, randomized, multicenter study of mucophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplant Study Group. Transplantation 1998; 65: 1450-1454
24. Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 2001; 71: 1091-1097
25. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, Tomlanovich S, Weinstein S, Inokuchi S, Kiberd B, Kittur D, Merion RM, Norman D, Shoker A, Wilburn R, Nicholls AJ, Arterburn S, Dumont E. Intravenous mycophenolate mofetil: safety, tolerability and pharmacokinetics. Clin Transplant 2000; 14: 179-188
26. Vasquez EM, Sifontis NM, Pollak R, Benedetti E. Impact of mycophenolete mofetil on recurrent rejection in kidney transplant patients. Clin Transplant 2001; 15: 253-257
27. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68-73
28. Budde K, Curtis J, Knoll G, Chan L, Neumayer HH, Seifu Y, Hall M. Enteric-coated Mycophenolate Sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-243
29. Pattou F, Vantyghem MC, Noel C, Kerr-Conte J, Gmyr V, Martinache I, Vandewalle B, N'Guyen H, Lecomte-Houcke M, Lefebvre J, Proye C. Sequential intraportal islet allografts in immunosuppressed type I diabetic patients: Preliminary results. Transplant Proc 2000; 32: 391-392
30. Oberholzer J, Toso C, Triponez F, Ris F, Bucher P, Demirag A, Lou J, Majno P, Buehler L, Philippe J, Morel P. Human Islet allotransplantation with Basiliximab in type 1 diabetic patients with end-stage renal failure. Transplant Proc 2002; 34: 823-825
31. Hao L, Lafferty KJ, Allison AC, Eugui EM. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990; 22: 876-879
32. Hao L, Wang Y, Chan SM, Lafferty KJ. Effect of Mycophenolate Mofetil on islet allografting to chemically induced or spontaneously diabetic animals. Transplant Proc 1992; 24: 2843-2844
33. Koulmanda M, Kovarik J, Mandel TE. Effect of Mycophenolate Mofetil with and without anti-CD4 (GK 1.5) on fetal islet iso-, allo-, and xenografts in NOD/Lt female mice. Transplant Proc 1997; 29: 2161-2162
34. Wennberg L, Groth CG, Tibell A, Zhu S, Liu J, Rafael E, Soderlund J, Biberfeld P, Morris RE, Karlsson-Parra A, Korsgren O. Triple drug treatment with Cyclosporine, Leflunomide and Mycophenolate Mofetil prevents rejection of pig islets transplanted into rats and primates. Transplant Proc 1997; 29: 2498
35. Wennberg L, Karlsson-Parra A, Sundberg B, Rafael E, Liu J, Zhu S, Groth CG, Korsgren O. Efficacy of immunosuppressive drugs in islet xenotransplantation. Transplantation 1997; 63: 1234-1242
36. Wijkstrom M, Song Z, Zhang J, Bari S, Sundberg B, Groth CG, Korsgren O, Wennberg L. Efficacy of Malononitriloamide 279 and 715 in islet xenotransplantation: A study in the pig-to-rat model. Transplant Proc 2000; 32: 1024
37. Wennberg L, Song Z, Bennet W, Zhang J, Nava S, Sundberg B, Bari S, Groth CG, Korsgren O. Diabetic rats transplanted with adult porcine islets and immunosuppressed with Cyclosporine A, Mycophenolate Mofetil, and Leflunomide remain normoglycemic for up to 100 d. Transplantation 2001; 71: 1024-1033
38. Hamamoto Y, Tsuura Y, Fujimoto S, Nagata M, Takeda T, Mukai E, Fujita J, Yamada Y, Seino Y. Recovery of function and mass of endogenous b-cells in streptozotocin-induced diabetic rats treated with islet transplantation. Biochem Biophys Res Commun 2001; 287: 104-109
39. Papalois A, Papalois B, Tzardis P, Bonatsos G, Nikolaou A, Katsorchis T, Pataryas T, Golematis B. Allotransplantation of pancreatic islets in rats using multiple donors. Transplant Proc 1994; 26: 3474-3476
40. Fotiadis C, Papalois A. The spleen as a site of transplantation and implantation of hepatocytes and islets of Langerhans. Arch Hell Med 2000; 17: 528-530
41. Yale JF, Chamelian M, Courchesne S, Vigeant C. Peripheral insulin resistance and decreased insulin secretion after Cyclosporine A treatment. Transplant Proc 1988; 20(3 Suppl 3): 985-988
42. Saudek F, Kazdova L, Nozickova M, Vrana A, Cihalova E, Ruzbarsky V. The effect of combination therapy with cyclosporine A and hydrocortisone on glucose metabolism in diabetic rats following pancreatic islet transplantation. Physiol Res 1995; 44: 79-86
43. Bramow S, Ott P, Thomsen Nielsen F, Bangert K, Tygstrup N, Dalhoff K. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001; 89: 133-139
44. Beger C, Menger MD. RS-61443 prevents microvascular rejection of pancreatic islet xenografts. Transplantation 1997; 63: 577-582
45. Xekouki P, Papalois A, Fotiadis C, Sfiniadakis J, Karampela E, Papadopoulou A, Grigoriou T, Sechas MN. In vivo test of two low doses of Mycophenolate Mofetil in an experimental model of islet allotransplantation. Transplant Proc 2002; 34: 1446-1448
46. Heuser M, Wolf B, Vollmar B, Menger M. Exocrine contamination of isolated islets of Langerhans deteriorates the process of revascularization after free transplantation. Transplantation 2000; 69: 756-761
47. Furuya H, Kimura T, Murakami M, Katayama K, Hirose K, Yamaguchi A. Revascularization and function of pancreatic islet isografts in diabetic rats following transplantation. Cell Transplant 2003; 12: 537-544
48. Chan FK, Shaffer EA. Cholestatic effects of cyclosporine in the rat. Transplantation 1997; 63: 1574-1578
49. Tedoriya T, Keogh AM, Kusano K, Savdie E, Hayward C, Spratt PM, Wilson M, Macdonald PS. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21: 976-982